Francine Goodman, PharmD

home / authors / francine-goodman-pharmd

Articles

Marketing Off-Label Uses: Shady Practices Within a Gray Market

Cathy L. Melvin, PhD, MPH;Timothy S. Carey, MD, MPH;John M. Oldham, MD;John W. Williams Jr, MD;Francine Goodman, PharmD;Thomas R. Linden, MD;W. Douglas Evans, PhD;Gary L. Kreps, PhD;Leah M. Ranney, PhD

August 7th 2009

For pharmaceutical companies, off-label use of a drug represents a substantial “gray market,” to which the company is unable to sell their product directly, yet may be a significant revenue stream. Some drugs have been used more for off-label purposes than for originally approved indications.1